title: Neuropeptide Y2 receptors as drug targets for the central regulation of body weight.
abstract: During the past decade, a detailed understanding has emerged of the aminergic and peptidergic neural pathways present within the brain that regulate appetite. Central among the peptide regulators is neuropeptide Y (NPY), a potent orexigenic agent that acts through five different receptor subtypes. Efforts to find novel appetite suppressant drugs that inhibit the interaction of NPY with either the NPY Y1 or NPY Y5 receptor subtypes have proven disappointing. Attempts have now been made to identify an NPY Y2 stimulator that will suppress appetite. Within the hypothalamus, NPY Y2 receptors have a predominantly presynaptic location where they act to inhibit NPY release. Stimulation of NPY Y2 receptors with synthetic peptide ligands or the gut derived peptide PY3-36 has been shown to reduce food intake. The NPY Y2 receptor has a wide distribution both within the brain and in the periphery. Stimulation of the NPY Y2 subtype at these sites produces a wide array of effects unrelated to changes in food intake. In consequence, the administration of both endogenous and exogenous agonists of the NPY Y2 receptor is likely to cause side effects, particularly regarding pituitary hormone release, as well as on the cardiovascular and gastrointestinal systems. The possibility that long-term NPY Y2 agonism could cause bone thinning and retinal angiogenesis are of particular concern and will need to be investigated as drug discovery moves forward.
authors.affiliation: Department of Angiology, Institut de Recherches Servier, Suresnes, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Félétou
authors.forename: Nigel R
authors.initials: NR
authors.lastname: Levens
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects*; D001921:Brain / Q000378:metabolism*; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000378:metabolism*
chemical_list: D019440:Anti-Obesity Agents; D008024:Ligands; D017476:Receptors, Neuropeptide Y; C095889:neuropeptide Y2 receptor